Clinical Trial Update: Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating a combination of an IL-17 inhibitor with a TNFα inhibitor for ankylosing spondylitis; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Interleukin-17 (IL-17) Inhibitor
• Tumor Necrosis Factor α (TNFα) Inhibitor

Snippet

Sponsor: The Affiliated Hospital Of Guizhou Medical University | Conditions: Ankylosing Spondylitis | Phase 4 | Status: NOT_YET_RECRUITING